For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$379.10
Thesis
Madrigal commercializes Rezdiffra, the first FDA-approved therapy for MASH (formerly NASH) — a large, previously untreated metabolic-liver-disease market. As the first mover with an oral, liver-biopsy-validated drug, it holds the category lead while the launch ramps across hepatology and endocrinology.
The investment case is a first-in-class commercial leader in a multi-billion-dollar metabolic market with high unmet need. Risks: it is effectively a single-product company, so the launch curve is the whole story; GLP-1s (which also improve liver endpoints) loom as both competition and potential combination partners, and reimbursement breadth governs uptake.
Catalysts
- Rezdiffra prescription and revenue ramp
- Label expansion (e.g. compensated cirrhosis)
- GLP-1 competitive and combination dynamics
- Payer coverage and prior-authorization trends
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 16Trial initiationClinicalTrials.gov
Phase 4 trial (NCT07848191) recruiting for Rezdiffra with concomitant therapies in adults with MASH and F2-F3 fibrosis.
- Nov 12Trial initiationClinicalTrials.gov
Phase 1 trial NCT07830758 of resmetirom in MASH and HFpEF updated to recruiting status.
- Nov 3Financial resultsSEC
Madrigal Pharmaceuticals filed 8-K (items 2.02, 9.01) disclosing results of operations and financial condition.
- Oct 16Trial initiationClinicalTrials.gov
Phase 4 trial (NCT07848191) of Rezdiffra with concomitant therapies in MASH patients with F2-F3 fibrosis now recruiting.
- Oct 16Trial initiationClinicalTrials.gov
Phase 1 trial of resmetirom in MASH and HFpEF initiated and recruiting (NCT07830758)
- Sep 21Trial initiationClinicalTrials.gov
Phase 1 trial initiation of resmetirom in MASH patients with HFpEF (NCT07830758, not yet recruiting)
- Sep 11Trial initiationClinicalTrials.gov
Madrigal initiates Phase 2 trial of resmetirom in children and adolescents with MASH (NCT07763015, recruiting).
- Aug 26Trial initiationClinicalTrials.gov
Madrigal initiates Phase 2 trial of resmetirom in post-liver transplant MASH patients (NCT07335601, recruiting).